Clinigen Clinical Trial Services (CTS) is the global leader in the sourcing, supply and delivery of comparator drugs for clinical research. After the recent acquisition of Idis Clinigen, CTS now has unrivalled global reach, strategic expertise and capacity to meet any comparator supply challenge. Our comprehensive services ensure all quality, regulatory, security and distribution hurdles are anticipated and overcome to leave our clients free to focus on completing vital clinical studies on time and on budget.
Our success has been built on the following foundations:
Clinigen CTS has supplied a massive range of different medicines for thousands of trials across the world; our service goes way beyond sourcing and delivery, however. We operate as a trusted strategic partner with pharmaceutical companies and contract research organisations (CROs) alike to ensure timely and cost-effective sourcing plus the complete package of regulatory, supply chain and quality assurance support. This comprehensive, end-to-end approach means our clients get a seamless, secure and hassle-free medicine and ancillary delivery service and, therefore, the peace of mind to focus on other core elements of running their programmes.
As a global leader and strategic partner, Clinigen CTS is setting new standards and developing novel services in trial supply and logistics, not just reacting to new trends. To this end our added value services, which have been developed in partnership with the world's top pharma companies, form an increasingly important part of our offering. Underpinning these new services is a desire to aid clients in their aim to improve trials efficiency, speed up studies, and reduce wastage of expensive and valuable medicines. We have embraced just-in-time principles and applied these to the specific needs of our clients in this specialised sector.
The most important added-value services we deliver include:
Clinical trial supplies procurement, labelling, supply logistics with global and local distribution.
If you would like to find out more please contact us: [email protected]